Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
VRTX: Ordinary SharesTotal Employee Number:
6,400Compare
Compare
Traded in other countries / regions
VRTX.USA0QZU.UKVRTX.MexicoVRTX34.BrazilVX1.GermanyVRTX.Austria1VRTX.Italy Index Membership
S&P 500NASDAQ 100Russell 1000Russell 3000MSCI World Index IPO Date
1991-07-31Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.65 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | 452.63 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 12.85 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.5 | |||||
3-Year EBITDA Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | 7.3 | |||||
3-Year FCF Growth Rate | -6.5 | |||||
3-Year Book Growth Rate | 10.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.81 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.41 | |||||
9-Day RSI | 47.35 | |||||
14-Day RSI | 53.12 | |||||
3-1 Month Momentum % | -0.13 | |||||
6-1 Month Momentum % | -6.07 | |||||
12-1 Month Momentum % | -9.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.02 | |||||
Quick Ratio | 2.57 | |||||
Cash Ratio | 1.87 | |||||
Days Inventory | 344.76 | |||||
Days Sales Outstanding | 57.92 | |||||
Days Payable | 98.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 1.52 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.24 | |||||
Operating Margin % | 38.16 | |||||
Net Margin % | 35.51 | |||||
EBITDA Margin % | 43.21 | |||||
FCF Margin % | 30.37 | |||||
OCF Margin % | 34.71 | |||||
ROE % | 24.37 | |||||
ROA % | 17.51 | |||||
ROIC % | 26.68 | |||||
3-Year ROIIC % | 5.25 | |||||
ROC (Joel Greenblatt) % | 157.07 | |||||
ROCE % | 24.39 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 28.79 | |||||
Forward PE Ratio | 25.56 | |||||
PE Ratio without NRI | 25.79 | |||||
Shiller PE Ratio | 54.97 | |||||
Price-to-Owner-Earnings | 38.67 | |||||
PS Ratio | 10.22 | |||||
PB Ratio | 6.37 | |||||
Price-to-Tangible-Book | 6.91 | |||||
Price-to-Free-Cash-Flow | 33.65 | |||||
Price-to-Operating-Cash-Flow | 29.47 | |||||
EV-to-EBIT | 23.3 | |||||
EV-to-Forward-EBIT | 22.59 | |||||
EV-to-EBITDA | 22.34 | |||||
EV-to-Forward-EBITDA | 21.48 | |||||
EV-to-Revenue | 9.65 | |||||
EV-to-Forward-Revenue | 9.26 | |||||
EV-to-FCF | 31.79 | |||||
Price-to-GF-Value | 0.96 | |||||
Price-to-Projected-FCF | 2.57 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
Price-to-Graham-Number | 2.81 | |||||
| Price-to-Net-Current-Asset-Value | 26.77 | |||||
| Price-to-Net-Cash | 990.59 | |||||
Earnings Yield (Greenblatt) % | 4.29 | |||||
FCF Yield % | 3.01 | |||||
Forward Rate of Return (Yacktman) % | -9.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12,218 | ||
| EPS (TTM) ($) | 16.86 | ||
| Beta | 0.0724 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.62 | ||
| Volatility % | 25.74 | ||
| 14-Day RSI | 53.12 | ||
| 14-Day ATR ($) | 15.494682 | ||
| 20-Day SMA ($) | 482.03675 | ||
| 12-1 Month Momentum % | -9.14 | ||
| 52-Week Range ($) | 362.5 - 533.67 | ||
| Shares Outstanding (Mil) | 253.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vertex Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-03 16:30 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-08-03 | In 23 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 11:20 | 445.77 (-0.28%) | ||
| Bernstein’s 42nd Annual Strategic Decisions Conference (SDC) | 2026-05-29 09:00 | 447.97 (+3.20%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-19 14:35 | 436.58 (+0.27%) | ||
| General meeting for 2026 | 2026-05-13 09:00 | 448.29 (+1.90%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 423.92 (-0.26%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 423.92 (-0.26%) |
Show
Entries
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(VRTX)'s stock price today?
The current price of VRTX is $485.39. The 52 week high of VRTX is $533.67 and 52 week low is $362.50.
When is next earnings date of Vertex Pharmaceuticals Inc(VRTX)?
The next earnings date of Vertex Pharmaceuticals Inc(VRTX) is 2026-08-03.
Does Vertex Pharmaceuticals Inc(VRTX) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(VRTX) does not pay dividend.
Guru Commentaries on NAS:VRTX
Press Release
Articles on Vertex Pharmaceuticals Inc
Headlines
See More- 1
Jul 08, 2026
Stock futures fall as Middle East tensions flare
Seeking Alpha • 3:31am
Jul 07, 2026
Biggest stock movers Tuesday: CRNX, RIVN, and more
Seeking Alpha • 4:01am
Jul 05, 2026
Notable healthcare headlines for the week: Abbott, AstraZeneca, and Eli Lilly in focus
Seeking Alpha • 8:05am
Jul 01, 2026
Vertex gains expanded indication for Casgevy in children as young as two
Seeking Alpha • 5:27pm
Jun 26, 2026
Tech stocks drag down Nasdaq for the week; Strategy and Arm Holdings among losers
Seeking Alpha • 3:06pm
Jun 12, 2026
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Benzinga • 6:30pm
Jun 11, 2026
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers